Qilu Hospital, Shandong University
Welcome,         Profile    Billing    Logout  
 94 Trials 
34 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Yanqing
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT04954677: A Real-time Quality Control System of Magnetic-controlled Capsule Gastroscopy

Completed
N/A
194
RoW
AI-box
Shandong University, Ancon Technologies Ltd, Shandong Provincial Hospital, Binzhou Medical University
Magnet Controlled Capsule Endoscopy
07/22
08/22
Hou, Ming
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting
3
85
RoW
Pomalidomide, Dexamethasone
Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma, Recurrent or Refractory
06/22
12/23
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Active, not recruiting
3
232
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
01/25
08/26
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
12/25
12/25
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Recruiting
3
150
RoW
Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B Cell Lymphoma (DLBCL)
07/24
12/25
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT06900920: A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

Not yet recruiting
3
199
RoW
TQB3473 Tablets, TQB3473 Placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Primary Immune Thrombocytopenia
03/27
12/27
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Recruiting
3
195
RoW
Orelabrutinib, Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Primary Immune Thrombocytopenia (ITP)
12/25
04/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

Recruiting
2a/2b
30
RoW
Orelabrutinib( lower dose), Orelabrutinib( higher dose)
Beijing InnoCare Pharma Tech Co., Ltd.
Primary Immune Thrombocytopenia
12/23
12/24
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Active, not recruiting
2
93
RoW
Ponatinib 30mg OD, Ponatinib 45mg OD
Otsuka Beijing Research Institute
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
07/22
12/25
LUMMICAR STUDY 1, NCT03975907: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1/2
121
RoW
CAR-BCMA T Cells
CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University
Multiple Myeloma
12/24
12/25
NCT06853444: A Phase 1/2 Study of ESG206 in Patients with Primary Immune Thrombocytopenia

Not yet recruiting
1/2
84
RoW
ESG206, ESG206-2
Shanghai Escugen Biotechnology Co., Ltd
Immune Thrombocytopenia (ITP)
03/26
04/27
Yang, Yun Sh
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
Chen, Yuguo
NCT05437900: INSIGHTFUL-FFR Clinical Trial

Recruiting
4
2500
Europe, RoW
Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care
CoreAalst BV, Insight Lifetech Co., Ltd.
Coronary Artery Disease, Acute Coronary Syndrome
06/26
06/30
NCT05922436: a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency

Not yet recruiting
3
378
NA
QLG2071, Clevidipine Butyrate Injectable Emulsion, Cleviprex®
Qilu Pharmaceutical (Hainan) Co., Ltd.
Hypertensive Emergency
05/24
05/24
Zuo, Xiuli
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

Active, not recruiting
2
92
RoW
Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group
Ganzhou Hemay Pharmaceutical Co., Ltd
Moderate to Severe Ulcerative Colitis
12/25
12/25
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Completed
N/A
500
RoW
Takeda
Colitis, Ulcerative, Crohn Disease
07/24
07/24
Peng, Jun
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
NCT06450067: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

Recruiting
N/A
200
RoW
Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
06/26
06/29
Hou, Yu
NCT06579287: A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

Recruiting
2
144
US, RoW
SHJ002, Atropine
Sunhawk Vision Biotech, Inc.
Myopia, Progressive
04/26
04/26
Wang, Donghai
NCT06479343: Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations

Recruiting
N/A
170
RoW
Liquid Embolic System (Tonbridge), Onyx Liquid Embolic System (Medtronic)
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Intracranial Arteriovenous Malformations
10/25
10/26
NCT05755516: Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms

Active, not recruiting
N/A
204
RoW
Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention)
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Intracranial Aneurysm
10/24
04/25
Zhong, Ning
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
Yan, Chuanzhu
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting
4
1312
RoW
GV-971, Placebo
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
06/29
12/29
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Completed
3
176
RoW
PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution
Tasly GeneNet Pharmaceuticals Co., Ltd
Charcot-Marie-Tooth Type 1A
03/24
03/24
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
SYS6020-004, NCT06688435: A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

Not yet recruiting
1
50
RoW
SYS6020 injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Myasthenia Gravis
12/28
05/33
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Yanqing
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT04954677: A Real-time Quality Control System of Magnetic-controlled Capsule Gastroscopy

Completed
N/A
194
RoW
AI-box
Shandong University, Ancon Technologies Ltd, Shandong Provincial Hospital, Binzhou Medical University
Magnet Controlled Capsule Endoscopy
07/22
08/22
Hou, Ming
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting
3
85
RoW
Pomalidomide, Dexamethasone
Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma, Recurrent or Refractory
06/22
12/23
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Active, not recruiting
3
232
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
01/25
08/26
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
12/25
12/25
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Recruiting
3
150
RoW
Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B Cell Lymphoma (DLBCL)
07/24
12/25
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT06900920: A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

Not yet recruiting
3
199
RoW
TQB3473 Tablets, TQB3473 Placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Primary Immune Thrombocytopenia
03/27
12/27
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Recruiting
3
195
RoW
Orelabrutinib, Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Primary Immune Thrombocytopenia (ITP)
12/25
04/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

Recruiting
2a/2b
30
RoW
Orelabrutinib( lower dose), Orelabrutinib( higher dose)
Beijing InnoCare Pharma Tech Co., Ltd.
Primary Immune Thrombocytopenia
12/23
12/24
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Active, not recruiting
2
93
RoW
Ponatinib 30mg OD, Ponatinib 45mg OD
Otsuka Beijing Research Institute
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
07/22
12/25
LUMMICAR STUDY 1, NCT03975907: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1/2
121
RoW
CAR-BCMA T Cells
CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University
Multiple Myeloma
12/24
12/25
NCT06853444: A Phase 1/2 Study of ESG206 in Patients with Primary Immune Thrombocytopenia

Not yet recruiting
1/2
84
RoW
ESG206, ESG206-2
Shanghai Escugen Biotechnology Co., Ltd
Immune Thrombocytopenia (ITP)
03/26
04/27
Yang, Yun Sh
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
Chen, Yuguo
NCT05437900: INSIGHTFUL-FFR Clinical Trial

Recruiting
4
2500
Europe, RoW
Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care
CoreAalst BV, Insight Lifetech Co., Ltd.
Coronary Artery Disease, Acute Coronary Syndrome
06/26
06/30
NCT05922436: a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency

Not yet recruiting
3
378
NA
QLG2071, Clevidipine Butyrate Injectable Emulsion, Cleviprex®
Qilu Pharmaceutical (Hainan) Co., Ltd.
Hypertensive Emergency
05/24
05/24
Zuo, Xiuli
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

Active, not recruiting
2
92
RoW
Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group
Ganzhou Hemay Pharmaceutical Co., Ltd
Moderate to Severe Ulcerative Colitis
12/25
12/25
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Completed
N/A
500
RoW
Takeda
Colitis, Ulcerative, Crohn Disease
07/24
07/24
Peng, Jun
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
NCT06450067: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

Recruiting
N/A
200
RoW
Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
06/26
06/29
Hou, Yu
NCT06579287: A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

Recruiting
2
144
US, RoW
SHJ002, Atropine
Sunhawk Vision Biotech, Inc.
Myopia, Progressive
04/26
04/26
Wang, Donghai
NCT06479343: Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations

Recruiting
N/A
170
RoW
Liquid Embolic System (Tonbridge), Onyx Liquid Embolic System (Medtronic)
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Intracranial Arteriovenous Malformations
10/25
10/26
NCT05755516: Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms

Active, not recruiting
N/A
204
RoW
Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention)
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Intracranial Aneurysm
10/24
04/25
Zhong, Ning
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
Yan, Chuanzhu
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting
4
1312
RoW
GV-971, Placebo
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
06/29
12/29
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Completed
3
176
RoW
PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution
Tasly GeneNet Pharmaceuticals Co., Ltd
Charcot-Marie-Tooth Type 1A
03/24
03/24
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
SYS6020-004, NCT06688435: A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

Not yet recruiting
1
50
RoW
SYS6020 injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Myasthenia Gravis
12/28
05/33

Download Options